Apogee Therapeutics (APGE) Price & Analysis

Compare

334 Followers

APGE Stock Chart & Stats

$70.39

-$0.82(-1.65%)

At close: Jan 08 4:00 PM EST

$70.39

-$0.82(-1.65%)

Day’s Range― - ―

52-Week Range$26.20 - $73.90

Previous CloseN/A

Volume109.80K

Average Volume (3M)728.98K

Market Cap

$4.81B

Enterprise Value$1.82B

Total Cash (Recent Filing)$527.29M

Total Debt (Recent Filing)$9.85M

Price to Earnings (P/E)―

Beta1.23

Next Earnings

Mar 10, 2026

EPS Estimate

-1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.11

Shares Outstanding54,833,588

10 Day Avg. Volume719,749

30 Day Avg. Volume728,978

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)3.49

Price to Sales (P/S)0.00

P/FCF Ratio-14.51

Enterprise Value/Market Cap0.38

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.54K

Enterprise Value/Ebitda-6.59

Forecast

1Y Price Target

$95.00

Price Target Upside34.96% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-4.17

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Drug EfficacyAPG777 demonstrated impressive efficacy in the Phase II AD trial with a strong exposure response correlation that bodes well for the Part B data expected mid-2026.

Financial PositionThe company raised $345M in an equity offering, resulting in a $913M cash and cash equivalents balance.

Pipeline DevelopmentShares continue to soar as we move into key fundamental pipeline data readouts in 2026.

Bears Say

Apogee Therapeutics News

Apogee Therapeutics reports Q3 net loss $65M vs. $49M last year

“Apogee is gearing up for a potentially transformative 2026 from a position of strength. With four key readouts...

20d ago

APGE

Apogee Therapeutics sees cash runway into 2H28

Cash, cash equivalents and marketable securities were $588.9 million as of September 30, 2025, compared to $621.2 million...

20d ago

APGE

Apogee Therapeutics announces interim Phase 1 results for APG333

Apogee Therapeutics (APGE) announced interim Phase 1 results from its first-in-human study of APG333, which demonstrated data supporting...

20d ago

APGE

Apogee Therapeutics price target raised to $70 from $60 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Apogee Therapeutics (APGE) to $70 from $60...

27d ago

APGE

Craig-Hallum bullish on Apogee Therapeutics, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $109 price target...

27d ago

APGE

Apogee Therapeutics initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $109 price target Published first on...

27d ago

APGE

Buy Rating for Apogee Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Apogee Therapeutics yesterday and set a price target...

17d ago

APGE

Apogee Therapeutics Reports Q3 2025 Financial Progress

Apogee Therapeutics, Inc. ( ($APGE) ) has released its Q3 earnings. Here is a breakdown of the information...

18d ago

APGE

Positive Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trials and Strategic Advancements

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating...

20d ago

APGE

Apogee Therapeutics Announces Positive Phase 1 Results

The latest update is out from Apogee Therapeutics ( ($APGE) ). On November 10, 2025, Apogee Therapeutics announced...

20d ago

APGE

Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment

Apogee Therapeutics, Inc. (($APGE)) announced an update on their ongoing clinical study. Apogee Therapeutics, Inc. is conducting a...

1M ago

APGE

Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know

Apogee Therapeutics, Inc. (($APGE)) announced an update on their ongoing clinical study. Apogee Therapeutics, Inc. is conducting a...

1M ago

APGE

Apogee Therapeutics’ Promising Update on Long-term APG777 Study for Atopic Dermatitis

Apogee Therapeutics, Inc. (($APGE)) announced an update on their ongoing clinical study. Apogee Therapeutics, Inc. is conducting a...

1M ago

APGE

Mizuho Securities Recommends Buy for Apogee Therapeutics Due to Promising APG777 Efficacy in Th2 Inflammatory Diseases

, an analyst from Mizuho Securities, has initiated a new Buy rating on Apogee Therapeutics (APGE). Mizuho Securities...

1M ago

APGE

APGE FAQ

What was Apogee Therapeutics, Inc.’s price range in the past 12 months?

Apogee Therapeutics, Inc. lowest stock price was $26.20 and its highest was $73.90 in the past 12 months.

What is Apogee Therapeutics, Inc.’s market cap?

Apogee Therapeutics, Inc.’s market cap is $4.81B.

When is Apogee Therapeutics, Inc.’s upcoming earnings report date?

Apogee Therapeutics, Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 100 days.

How were Apogee Therapeutics, Inc.’s earnings last quarter?

Apogee Therapeutics, Inc. released its earnings results on Nov 10, 2025. The company reported -$1.11 earnings per share for the quarter, beating the consensus estimate of -$1.125 by $0.015.

Is Apogee Therapeutics, Inc. overvalued?

According to Wall Street analysts Apogee Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Apogee Therapeutics, Inc. pay dividends?

Apogee Therapeutics, Inc. does not currently pay dividends.

What is Apogee Therapeutics, Inc.’s EPS estimate?

Apogee Therapeutics, Inc.’s EPS estimate is -1.

How many shares outstanding does Apogee Therapeutics, Inc. have?

Apogee Therapeutics, Inc. has 54,833,588 shares outstanding.

What happened to Apogee Therapeutics, Inc.’s price movement after its last earnings report?

Apogee Therapeutics, Inc. reported an EPS of -$1.11 in its last earnings report, beating expectations of -$1.125. Following the earnings report the stock price went up 3.765%.

Which hedge fund is a major shareholder of Apogee Therapeutics, Inc.?

Currently, no hedge funds are holding shares in APGE

Apogee Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-38.41%

Trailing 12-Months

Asset Growth

-19.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics (APGE) Earnings & Revenues

Historic Earnings Reports

APGE Stock 12 Month Forecast

Average Price Target

$95.00

▲(34.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","73":"$73","116":"$116","51.5":"$51.5","94.5":"$94.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,51.5,73,94.5,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.59,61.08307692307692,65.57615384615384,70.06923076923077,74.5623076923077,79.05538461538461,83.54846153846154,88.04153846153847,92.53461538461539,97.0276923076923,101.52076923076923,106.01384615384615,110.50692307692307,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.59,59.54461538461539,62.49923076923077,65.45384615384616,68.40846153846154,71.36307692307693,74.31769230769231,77.27230769230769,80.22692307692307,83.18153846153847,86.13615384615385,89.09076923076924,92.04538461538462,{"y":95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.59,57.621538461538464,58.653076923076924,59.684615384615384,60.71615384615385,61.74769230769231,62.77923076923077,63.81076923076923,64.8423076923077,65.87384615384616,66.90538461538462,67.93692307692308,68.96846153846154,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.49,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.33,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >